BRIEF-Omeros presents late-stage trial data of eye drug at American Academy of Ophthalmology meeting

Tue Nov 19, 2013 7:10am EST

Nov 19 (Reuters) - Omeros Corp : * Reports phase 3 oms302 clinical data presented at the annual American academy

of ophthalmology meeting * Says in the clinical trials, oms302 reduced incidence of miosis * Source text for Eikon * Further company coverage

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.